Using CRISPR/Cas9, they showed that BLM deletion in prostate cancer cells inhibits cell proliferation by downregulating pAKT and pRAS, which leads to increased reactive oxygen species production (Chen et al., 2019). Here, BLM is linked to prostate carcinoma.